scPharmaceuticals Inc. Quarterly Interest Expense in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
scPharmaceuticals Inc. quarterly/annual Interest Expense history and growth rate from Q2 2017 to Q3 2024.
  • scPharmaceuticals Inc. Interest Expense for the quarter ending September 30, 2024 was $1.85M, a 10.2% decline year-over-year.
  • scPharmaceuticals Inc. Interest Expense for the twelve months ending September 30, 2024 was $8.18M, a 2.33% increase year-over-year.
  • scPharmaceuticals Inc. annual Interest Expense for 2023 was $8.12M, a 146% increase from 2022.
  • scPharmaceuticals Inc. annual Interest Expense for 2022 was $3.3M, a 28.2% increase from 2021.
  • scPharmaceuticals Inc. annual Interest Expense for 2021 was $2.58M, a 0.46% decline from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $8.18M $1.85M -$210K -10.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $8.39M $2.13M +$124K +6.17% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $8.26M $2.1M +$140K +7.14% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $8.12M $2.09M +$132K +6.74% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 $7.99M $2.06M +$1.68M +446% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $6.31M $2.01M +$1.56M +350% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $4.75M $1.96M +$1.44M +279% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $3.3M $1.96M +$1.34M +216% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 $1.96M $377K -$290K -43.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $2.25M $447K -$204K -31.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $2.46M $518K -$118K -18.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.58M $621K -$36K -5.48% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $2.61M $667K +$12K +1.83% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $2.6M $651K +$12K +1.88% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $2.59M $636K $0 0% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $2.59M $657K +$11K +1.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 $2.58M $655K +$257K +64.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $2.32M $639K +$270K +73.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $2.05M $636K +$282K +79.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $1.77M $646K +$275K +74.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 $1.49M $398K +$38K +10.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $1.45M $369K +$10K +2.79% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $1.44M $354K +$12K +3.51% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $1.43M $371K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 $360K +$31K +9.42% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $359K +$227K +172% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $342K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q3 2017 $329K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $132K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.